Zynerba Pharmaceuticals Inc. (ZYNE) announced Monday morning that its Phase 2 study of ZYN002 in adult epilepsy patients with focal seizures did not demonstrate a statistically significant reduction of focal seizures.
from RTT - Before the Bell http://ift.tt/2vAtWur
via IFTTT
No comments:
Post a Comment